Genetic study of HDR brachytherapy for low-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low-risk or early intermediate-risk prostate cancer.
- Your expected lifespan is at least 10 years.
- You haven't had hormone therapy, surgery, or radiation for prostate cancer.
- You are able to have an MRI and are not on blood thinners that can't be paused.
- You are in good overall health (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
This trial studies a targeted, high-dose form of radiation (HDR brachytherapy) for prostate cancer that has come back after earlier radiation treatment. It aims to treat a limited (one-area) recurrence while trying to avoid serious late side effects from repeat radiation.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
This trial tests a focused form of radiation placed inside the prostate to treat only the cancer area in people with low-risk prostate cancer. It aims to control the cancer while limiting treatment to a smaller area.
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
This study tests a stronger, focused radiation plan for intermediate to higher-risk prostate cancer. It combines a high-dose internal radiation “boost” with external radiation to try to improve cancer control while keeping side effects manageable.
Hear when a new Localized Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.